CA
NZ
UK
AU
IND
US
Shuttle Pharmaceuticals (NASDAQ:SHPH) rose 9.25% on June 23, 2026, closing at $3.84 after a $0.33 per-share move. The session’s advance came as post-split trading drove a radioenhancer rebound, based on the available company disclosures and trading context.
Viking Therapeutics (NASDAQ:VKTX) rose 7.54% on June 23, 2026, closing at $34.81 after a $2.44 per-share move. The session’s advance came as new institutional coverage renewed obesity drug interest, based on the available company disclosures and trading context.
Anteris Technologies Global (NASDAQ:AVR) rose 7.19% on June 23, 2026, closing at $10.28 after a $0.69 per-share move. The session’s advance came as optimism around the Medtronic partnership supported the valve pipeline, based on the available company disclosures and trading context.
KORU Medical Systems (NASDAQ:KRMD) rose 6.99% on June 23, 2026, closing at $4.13 after a $0.27 per-share move. The session’s advance came as 22% revenue growth sustained home-infusion momentum, based on the available company disclosures and trading context.
Delcath Systems (NASDAQ:DCTH) rose 6.78% on June 23, 2026, closing at $12.29 after a $0.78 per-share move. The session’s advance came as HEPZATO sales outlook sustained commercial momentum, based on the available company disclosures and trading context.
Biodesix (NASDAQ:BDSX) rose 10.43% on June 23, 2026, closing at $19.16 after a $1.81 per-share move. The session’s advance came as higher revenue outlook extended lung diagnostics momentum, based on the available company disclosures and trading context.
WidePoint (NYSEAMERICAN:WYY) rose 11.38% on June 23, 2026, closing at $15.27 after a $1.56 per-share move. The session’s advance came as federal contract momentum extended the cybersecurity rally, based on the available company disclosures and trading context.
Seres Therapeutics (NASDAQ:MCRB) rose 6.82% on June 23, 2026, closing at $7.05 after a $0.45 per-share move. The session’s advance came as cash runway extension supported the microbiome therapy stock, based on the available company disclosures and trading context.
KALA BIO (NASDAQ:KALA) fell 11.86% on June 23, 2026, closing at $3.12 after a $0.42 per-share move. The session’s decline came as post-split profit taking pressured the ocular biotech, based on the available company disclosures and trading context.
Jade Biosciences (NASDAQ:JBIO) rose 12.96% on June 23, 2026, closing at $21.97 after a $2.52 per-share move. The session’s advance came as lupus programme anticipation drove the clinical-stage biotech, based on the available company disclosures and trading context.
Please wait processing your request...